Redditors Are Buying Eli Lilly And Co (LLY) Ahead of Potential End of AI Trade. Here’s Why

We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying.

Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, immunology and neuroscience, Redditors believe the company can offset any potential weakness in GLP-1 drugs amid the US government’s push to lower prices.

The company recently achieved the $1 trillion market cap milestone. The stock is up 36% so far this year. LLY bulls believe it has more upside potential amid strong growth from weight-loss drugs and other treatments, including diabetes, Alzheimer’s, and cancer.

While the stock’s P/E ratio remains elevated, some analysts believe it deserves a premium due to strong revenue growth. Over the past 12 months, LLY saw about 45% revenue growth, higher than its peers.

Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its third quarter 2025 investor letter:

“Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company currently best known for its GLP-1 treatments for diabetes and obesity. Shares declined after Phase 3 data for Lilly’s oral orforglipron in obesity fell short of elevated investor expectations. Investors had anticipated roughly 13% to 14% placebo-adjusted weight loss, while the trial showed 11.5%. The stock was also pressured by broader regulatory uncertainty related to potential sector tariffs and drug pricing risks. We view these risks as manageable and believe Lilly is among the least exposed pharmaceutical companies to both. We continue to believe orforglipron will be an important treatment option, as physicians and patients are likely to value the convenience of a daily oral therapy. Long term, we expect the GLP-1 drug class to become the standard of care for diabetes and obesity, ultimately representing a $150 billion-plus market, and believe Lilly possesses the leading portfolio in this category. In our view, GLP-1 adoption remains in the early stages, and continued uptake should drive a near doubling of Lilly’s total revenues by 2030.”

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.